We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Jordanian drugmaker Hikma Pharmaceuticals will sell off two drugs and relinquish marketing rights to a third to avoid tangling with the Federal Trade Commission on its planned purchase of a Boehringer Ingelheim subsidiary. Read More
Regular price reevaluations can lower drug prices in individual European countries, but the only way to ensure significant price cuts is through EU-wide collaboration, according to a new report. Read More
After years of uncontrolled spending, the UK’s troubled Cancer Drugs Fund has presented the National Health Service with a restructuring plan to get back on track. Read More
Six new drugs scored wins at the European Medicines Agency, scooping up recommendations for marketing authorization from the Committee for Medicinal Products for Human Use. Read More
Lawmakers grilled FDA interim Commissioner Stephen Ostroff during a budget appropriations subcommittee hearing Thursday over the agency’s request for $5.1 billion for fiscal 2017. Read More
Pay-for-delay deals don’t have to be in cash form for them to be at risk of an antitrust suit, according to a recent federal appellate panel ruling. Read More
The Senate was urged Thursday to permanently reauthorize the Creating Hope Act, which would provide market incentives to pharmaceutical companies to develop drugs for pediatric rare diseases, ahead of a March 9 markup of the bill by the Senate HELP Committee. Read More